British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...

Thanks largely to news of a crucial legal settlement, GSK (NYSE: GSK) was one of the better-performing big pharma stocks on ...

GSK plc (NYSE:GSK – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 10,740,675 shares changed hands during mid-day trading, an increase of 196% from the previous ...

Health-care companies rose as traders hedged their bets on the outlook for growth in the sector. Bayer shares fell sharply after Washington state's top court granted a petition for review in a case ...

GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.